Date de publication: 21 octobre 2020
Promoteur – Intermédiaire FinancierPRIVATE ENTITY(IES)
An investment loan to support i) the purchase, warehousing and distribution of diagnostic devices for COVID-19 in sub-Saharan Africa and ii) the subsequent technology transfer and capex for the development of manufacturing capacity of diagnostic tests for endemic diseases (malaria, yellow fever and measles/rubella).
The project aims to finance up to 100% of the cost connected with the purchase of point-of-care diagnostic devices for COVID-19 (or critical inputs for manufacturing) for subsequent distribution to the National Health Services of sub-Saharan African countries and up to 75% of the costs to both furnish and validate a production unit in Senegal for the manufacturing of diagnostic tests for endemic diseases (dengue, yellow fever, malaria, HIV) and the necessary technical and development costs to implement the production process. The project will be developed in Dakar, Senegal.
- Santé - Santé humaine et action sociale
Montant BEI envisagé (montant approximatif)
EUR 20 million
Coût total (montant approximatif)
EUR 28 million
The project mainly concerns investments that if the project were in the EU, would fall under the annex II of the Environmental Impact Assessment (EIA) directive (2014/52/EU), referring to the manufacture of diagnostic products. Full environmental details will be verified during appraisal, including evidence of any screening by the competent authorities and a conformity check with applicable European directives as well as other environmental and social details.
Passation des marchés
The Bank will require the Promoter to ensure that implementation of the project will be done in accordance with the Bank's Guide to Procurement.
Approuvé - 16/12/2020